RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Trillium Therapeutics Stock

Trillium Therapeutics Stocks 2024

Trillium Therapeutics Stocks

84.6 M

Ticker

TRIL.TO

ISIN

CA89620X5064

WKN

A12FG3

In 2024, Trillium Therapeutics had 84.6 M outstanding stocks, a 0% change from the 84.6 M stocks in the previous year.

The Trillium Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2025e84.6
2024e84.6
2023e84.6
2022e84.6
2021e84.6
202084.6
201925.26
201813.91
20179.77
20167.82
20156.64
20144.2
20131.36
20120.62
20110.6
20100.52
20090.46
20080.37
20070.24
20060.18
20050.18
20040.04

Trillium Therapeutics shares outstanding

The number of shares was Trillium Therapeutics in 2023 — This indicates how many shares 84.6 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Trillium Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Trillium Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Trillium Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Trillium Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Trillium Therapeutics Aktienanalyse

What does Trillium Therapeutics do?

Trillium Therapeutics Inc is a Canadian biotech company specializing in the development of cancer treatments. The company was founded in 2005 and is based in Mississauga, Ontario. Trillium Therapeutics is involved in various areas of research. One of its key focuses is the development of immunotherapies for cancer treatment. The company is working on the discovery and development of novel targeted immunotherapies that aim to specifically target tumors and utilize the body's immune system to fight cancer. Another focus of Trillium Therapeutics is the development of cancer drugs targeting specific gene mutations. These drugs are intended to inhibit or kill cancer cells by specifically targeting the genetically altered cells. Trillium Therapeutics is also involved in the discovery and development of drugs for the treatment of immuno-oncological diseases, which are diseases where the body's immune system fights against its own cells, such as autoimmune diseases. The business model of Trillium Therapeutics is based on the research and development of innovative cancer drugs. The company collaborates closely with leading cancer centers and clinics to identify and test new therapeutic approaches. Trillium Therapeutics has a number of products and therapies in development. One example is TTI-621, an immunotherapy that aims to recognize and kill tumor cells. TTI-621 is currently in clinical trials for the treatment of T-cell lymphomas and glioblastomas, a type of brain tumor, and has shown promising results. Another product that Trillium Therapeutics is working on is TTI-622. It is also an immunotherapy that focuses on inhibiting T-cells to support controlled tumor growth. TTI-622 is currently in clinical trials in patients with advanced cancer. The company is also working on a number of preclinical programs aimed at expanding treatment options for cancer patients. These programs target various biological targets, including immunomodulation, induction of apoptosis, and inhibition of DNA repair. Trillium Therapeutics has received several awards and recognitions in recent years, including inclusion in the Russell 3000 Index, being named the top biotechnology company on the BioCentury Future Leaders List, and being recognized as one of the top 10 most exciting biotech companies in Canada. Overall, Trillium Therapeutics is a leading biotech company focused on the development of innovative cancer therapies. The company is at the forefront of technology and collaborates closely with leading cancer centers and clinics to develop products that can improve the lives of cancer patients. Trillium Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Trillium Therapeutics's Shares Outstanding

Trillium Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Trillium Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Trillium Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Trillium Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Trillium Therapeutics stock

How many stocks are there of Trillium Therapeutics?

The current number of stocks of Trillium Therapeutics is 84.6 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Trillium Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Trillium Therapeutics evolved in recent years?

The number of shares of Trillium Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Trillium Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Trillium Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Trillium Therapeutics pay?

Over the past 12 months, Trillium Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Trillium Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Trillium Therapeutics?

The current dividend yield of Trillium Therapeutics is .

When does Trillium Therapeutics pay dividends?

Trillium Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Trillium Therapeutics?

Trillium Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Trillium Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Trillium Therapeutics located?

Trillium Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Trillium Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Trillium Therapeutics from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Trillium Therapeutics pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Trillium Therapeutics in the year 2023?

In the year 2023, Trillium Therapeutics distributed 0 USD as dividends.

In which currency does Trillium Therapeutics pay out the dividend?

The dividends of Trillium Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Trillium Therapeutics

Our stock analysis for Trillium Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Trillium Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.